[Use of immunosuppressive agents in systemic diseases].
The use of immuno-suppressive agents in systemic diseases where the auto-immune origin is probable or certain is not yet based on definite physiopathological evidence. Therefore, it seems essential to use this treatment which has definite side effects only in cases where the progressive nature of the disease, renal complications or the incomplete or nil efficacy of less agressive treatments, leave no choice.
D003520:Cyclophosphamide / Q000627:therapeutic use; D003882:Dermatomyositis / Q000188:drug therapy; D006505:Hepatitis / Q000188:drug therapy; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D010488:Polyarteritis Nodosa / Q000188:drug therapy
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide
Utilisation des immuno-suppresseurs dans les maladies systémiques.